BridgeBio Pharma Inc vs Teladoc Health Inc — how do they compare? BridgeBio Pharma Inc trades at $83.81 (market cap $16.36B), while Teladoc Health Inc trades at $6.83 (market cap $1.24B). The key difference: BridgeBio Pharma Inc is far larger — about 13.2× Teladoc Health Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | TDOC | |
|---|---|---|
Market Cap | $16.36B | $1.24B |
Sector | Health | Health |
52-Week High | $90.17 | $9.72 |
52-Week Low | $47.29 | $4.47 |
Enterprise Value | $18.14B | $1.50B |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →